|
|
||||||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
1 University of Toledo Health Science Campus
2 University of Toledo- Health Science Campus
3 University of Toledo, Health Science Campus
4 University of Toledo
5 National Institute on Aging/NIH
6 University of Toledo College of Medicine
7 Univrsity of Toledo, Health Science Campus
8 Medical University of South Carolina
* To whom correspondence should be addressed. E-mail: joseph.shapiro{at}utoledo.edu.
The cardiotonic steroid, marinobufagenin (MBG) has been implicated in the pathogenesis of experimental uremic cardiomyopathy which is characterized by progressive cardiac fibrosis. We examined whether the transcription factor, Fli-1 might be involved in this process. Fli-1 knockdown demonstrated greater cardiac collagen-1 expression and fibrosis compared to wild type mice; both developed increased cardiac collagen expression and fibrosis following 5/6th nephrectomy. There was a strong inverse relationship between the expressions of Fli-1 and procollagen in primary culture of rat cardiac and human dermal fibroblasts as well as a cell line derived from renal fibroblasts, and MBG induced decreases in nuclear Fli-1 as well as increases in procollagen-1 expression in these cells. Transfection of a Fli-1 expression vector prevented increased procollagen-1 expression from MBG. MBG exposure induced a rapid translocation of the delta isoform of protein kinase C (PKC
) to the nucleus. This translocation was prevented by pharmacological inhibition of phospholipase C, and MBG induced increases in procollagen-1 expression were prevented with a PKC
but not a PKC
specific inhibitor. Finally, immunoprecipitation studies strongly suggest that MBG induced phosphorylation of Fli-1. We feel these data support a causal relationship between MBG induced translocation of PKC
which result in phosphorylation of as well as decreases in nuclear Fli-1 expression which, in turn, leads to increases in collagen production. Should these findings be confirmed, we speculate that this pathway may represent a therapeutic target for uremic cardiomyopathy as well as other conditions associated with excessive fibrosis.
This article has been cited by other articles:
![]() |
J. Tian, A. Shidyak, S. M. Periyasamy, S. Haller, M. Taleb, N. El-Okdi, J. Elkareh, S. Gupta, S. Gohara, O. V. Fedorova, et al. Spironolactone Attenuates Experimental Uremic Cardiomyopathy by Antagonizing Marinobufagenin Hypertension, December 1, 2009; 54(6): 1313 - 1320. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH |
| Visit Other APS Journals Online |